The Part 1 dose escalation phase of the study will evaluate two treatment schedules of CMP-001 (at doses of 1 mg, 3 mg, 5 mg, 7.5 mg or 10 mg) administered in combination with pembrolizumab, designated as Schedule "A" or "B". There will be approximately 60 subjects enrolled into the Part 1 dose escalation phase of the study.